Sareum (LON:SAR) Stock Price Up 13.2% – Here’s What Happened

Sareum Holdings plc (LON:SAR)’s share price was up 13.2% on Friday . The stock traded as high as GBX 15 ($0.19) and last traded at GBX 15 ($0.19). Approximately 467,324 shares were traded during mid-day trading, an increase of 3% from the average daily volume of 455,494 shares. The stock had previously closed at GBX 13.25 ($0.17).

Sareum Price Performance

The company has a market cap of £19.18 million, a P/E ratio of -3.64 and a beta of -1.08. The company’s 50-day moving average price is GBX 16.60 and its 200-day moving average price is GBX 22.52.

Sareum (LON:SAR) last released its earnings results on Tuesday, March 25th. The company reported GBX (0.90) (($0.01)) earnings per share (EPS) for the quarter. On average, equities research analysts predict that Sareum Holdings plc will post -3.8 EPS for the current year.

Insider Buying and Selling

In other Sareum news, insider Stephen Parker bought 84,033 shares of Sareum stock in a transaction that occurred on Wednesday, March 26th. The stock was acquired at an average price of GBX 12 ($0.15) per share, for a total transaction of £10,083.96 ($13,003.17). 5.02% of the stock is owned by corporate insiders.

About Sareum

Sareum is a specialist drug development company delivering targeted small molecule therapeutics to improve the treatment of cancer and autoimmune diseases. The Company aims to generate value through licensing its candidates to international pharmaceutical and biotechnology companies at the preclinical or early clinical trials stage.
Sareum is advancing internal programmes focused on distinct dual tyrosine kinase 2 (TYK2) / Janus kinase 1 (JAK1) inhibitors through preclinical development as therapies for autoimmune diseases, including the ‘cytokine storm’ immune system overreaction to Covid-19 and other viral infections, (SDC-1801) and cancer immunotherapy (SDC-1802).
Sareum also has an economic interest in SRA737, a clinical-stage oral, selective Checkpoint kinase 1 (Chk1) inhibitor that targets cancer cell replication and DNA damage repair mechanisms.